Alexis Ogdie is a Rheumatology/Immunology physician affiliated with Hospital of the University of Pennsylvania. OpenAlex indexes 439 publications with 17,862 citations (h-index 59); ClinicalTrials.gov lists 8 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Rheumatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Civic Center Blvd
Philadelphia, PA 191045127
Telephone
215-662-2454Provider last certified this registry record 23 Feb 2026.
Clinical trials
- Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Sponsor: University of Pennsylvania
- Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)
Sponsor: University of Pennsylvania
- Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
Sponsor: University of Pennsylvania
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20255 payments$20,950openpaymentsdata.cms.gov ↗
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20253 payments$11,250openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year202535 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.9%TNF inhibitor14.4%Enbrel Sureclick100%Part D<11 patientsPhosphodiesterase 4 Inhibitor8.9%Otezla100%Part D<11 patients+ 5 more classes in this area
Nervous system
25.8%Opioid Agonist10.4%Oxycodone Hcl100%Part D<11 patientsNonsteroidal Anti-inflammatory Drug8.9%Ibuprofen100%Part D<11 patients+ 1 more class in this area
Antiparasitic
11.3%Antimalarial11.3%Hydroxychloroquine Sulfate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2013–2025 per NIH RePORTER. The latest:
- Predicting poor response to therapy and developing interventions to improve outcomes
University of Pennsylvania
FY2025$164,830K24AR086265 - Refining Outcome Measurement in Psoriatic Arthritis: Preparation for Pragmatic Trials
University of Pennsylvania
FY2019$70,566R01AR072363 - Refining Outcome Measurement in Psoriatic Arthritis: Preparation for Pragmatic Trials
University of Pennsylvania
FY2018$247,235R01AR072363
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Does biologic therapy impact the development of PsA among patients with psoriasis?
Annals of the Rheumatic Diseases
2022 - The epidemiology of psoriatic arthritis: A literature review
Best Practice & Research Clinical Rheumatology
2021 - Psoriatic arthritis and the association with cardiometabolic disease: a narrative review
Therapeutic Advances in Musculoskeletal Disease
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Mohamed Gad, MD, MPH
Hospital of the University of Pennsylvania
Lawrence Wechsler, MD
Hospital of the University of Pennsylvania
John Hirshfeld, MD
Hospital of the University of Pennsylvania
Noelle Frey, MD
Hospital of the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”